Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian Cancer

NCT06483048 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06483048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06483048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
September 20, 2024
Completion date
September 30, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, recurrent fallopian tube carcinoma, recurrent fallopian tube carcinosarcoma, recurrent female reproductive system carcinoma, recurrent ovarian carcinoma, recurrent ovarian carcinosarcoma, recurrent platinum-resistant fallopian tube carcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal carcinosarcoma, refractory fallopian tube carcinoma, refractory female reproductive system carcinoma, refractory ovarian carcinoma, refractory primary peritoneal carcinoma